Company History - CDI LABS

About

CDI Laboratories is the NextGen Proteomics™ company, a result of intensive efforts and advances made by synthetic biologists at the Johns Hopkins University School of Medicine.

The company was created by scientists for scientists to address critical needs required accelerate research, advance discoveries, and translate these discoveries into novel products and services that improve human health. Our flagship product, HuProt™ — the Human Proteome Microarray — has gone through several upgrades in content & print quality.

News Releases

An archive of public press-releases announcing important events at CDI Laboratories.

APRIL 2017 – CDI LABORATORIES AND NEOBIOTECHNOLOGIES FORM ALLIANCE TO DISTRIBUTE CDI’S 2500 MONOSPECIFIC TRANSCRIPTION FACTOR ANTIBODIES

MAY 2017 – CDI LABS EXPANDS HUPROT™ – THE HIGHEST CONTENT HUMAN PROTEOME MICROARRAY IN THE WORLD

NOVEMBER 2017 – THE WORLD’S LARGEST HUMAN PROTEOME MICROARRAY: ADVANCING PROTEIN BIOMARKER DISCOVERY

NOVEMBER 2017 – CDI LABS CITES NEW RESEARCH IDENTIFYING EARLY LUNG CANCER AUTOANTIBODY BIOMARKERS USING HUPROT™

MARCH 2018 – CDI LABS COLLABORATES ON DISCOVERY OF NEW BIOMARKERS FOR ZIKA INFECTION

MARCH 2018 – CDI LABS’ MONOCLONAL ANTIBODY DEVELOPMENT PIPELINE FEATURED IN NATURE METHODS

APRIL 2018 – CDI LABORATORIES INC. OPENS $17M BIOTECH LAB IN MAYAGÜEZ

MARCH 2019 – CDI LABS RELEASES HUPROT™ V4.0 – ADDING ADDITIONAL CONTENT TO LARGEST CONTENT HUMAN PROTEOME MICROARRAY IN THE WORLD

MARCH 2019 – CDI LABS TO SHOWCASE IMMUNO-ONCOLOGY PRODUCTS & SERVICES AT AACR 2019

FEBRUARY 2020 – CDI LABS LAUNCHES TWO NEW POWERFUL ASSAYS TO ITS BIOMARKER DISCOVERY PLATFORM

SEPTEMBER 2020 – CDI LABS HUPROT™ PROTEIN ARRAYS INSTRUMENTAL IN RECENT STUDY OF MULTISYSTEM INFLAMMATORY SYNDROME IN CHILDREN (MIS-C)

JANUARY 2023 – BROADOAK CAPITAL PARTNERS INVESTS IN CDI LABORATORIES TO EXPAND AND SCALE ANTIBODY BIOMARKER DISCOVERY PLATFORMS

Company History Timeline

2001 – Co-founder Heng Zhu publishes his breakthrough paper featuring the first full eukaryotic proteome array with Michael Snyder.

Global Analysis of Protein Activities Using Proteome Chips. Heng Zhu, et al. Science (2001) DOI: 10.1126/science.1062191

2008 – CDI Labs is founded to commercialize technologies created by the Johns Hopkins University School of Medicine.

Company founded as a collaboration with Johns Hopkins University and a $477K seed grant from the Puerto Rico Science, Technology, and Research Trust.

2009 – Future Director of Proteomic Sciences Shaohui Hu publishes on initial HuProt™ technology with Heng Zhu.

Profiling the Human Protein-DNA Interactome Reveals ERK2 as a Transcriptional Repressor of Interferon Signaling. Shaohui Hu, et al. Cell (2009) DOI: 10.1016/j.cell.2009.08.037

2010 – First SBIR Grant.

SBIR Phase 1 Grant: Development of an Attenuated Babesia Vaccine for Cattle.

2010 – First STTR Grant.

STTR Phase I grant awarded to produce and commercialize monoclonal antibodies used to study brain-expressed proteins that are implicated in human mental disorders. The antibodies were validated using CDI’s proprietary antigen microarrays.

2011 – Additional funding.

$800K note from the Puerto Rico Science Trust.

2012 – Major $13.5M NIH Roadmap grant to devlop new reagents validated by HuProt™ microarrays.

Co-founders awarded $13.8M grant from NIH Protein Capture Reagents Program to further develop company technology in collaboration with Johns Hopkins University: Production of Affinity Reagents for Human Transcription Factors (U54) RFA-RM-10-017

2012 – First publication of finalized HuProt™ technology.

Rapid identification of monospecific monoclonal antibodies using a human proteome microarray. J Jeong, et al. Molecular & Cellular Proteomics (2012) DOI: 10.1074/mcp.O111.016253

2013 – The first VirD™ prototype was developed in 2013 by CDI’s Director of Proteomic Sciences Shaohui Hu, working with Prashant Desai, Heng Zhu, and others at the Johns Hopkins University School of Medicine.

VirD: A Virion Display Array for Profiling Functional Membrane Proteins. S. Hu, et al. Anal. Chem. (2013) DOI: 10.1021/ac401795y

2015 – CDI invited to attend White House Demo Day.

CEO Ignacio Pino & VP Scott Paschke represents company as a ‘Presidential Ambassador for Global Entrepreneurship’ following invitation by the Obama White House.

2016 – Results of CDI’s work for the NIH Protein Capture Reagents Program are published in Nature Methods.

The NIH Protein Capture Reagents Program (PCRP): a standardized protein affinity reagent toolbox. S. Blackshaw, et al. Nature Methods. (2016). DOI: 10.1038/nmeth.4013

2016 – Additional STTR Grant.

STTR Phase 1 Grant: Validation of immune-based biomarkers for endometriosis.

2016 – Additional STTR Grant.

STTR Phase 1 Grant: Monospecific monoclonal antibodies against human protein complexes on an interactome- wide scale.

2018 – Collaborators use HuProt™ to show that patients' pre-treatment autoantibody fingerprints can predict adverse events to cancer immunotherapy.

Baseline antibody profiles predict toxicity in melanoma patients treated with immune checkpoint inhibitors. Gowen, et al. J Transl Med (2018) DOI: 10.1186/s12967-018-1452-4

2019 – Co-founder Heng Zhu publishes additional work on VirD™ membrane-embedded arrays.

Development and application of a high-content virion display human GPCR array. Heng Zhu, et al. Nature Communications (2019) DOI: 10.1038/s41467-019-09938-9

2019 – Antygen™ brand launched.

Immune profiling of patient antibodies using the most comprehensive antigen-specific biomarker assays ever developed. Services to industry and academia.

2019 – mMabs™ brand launched.

Highly-validated monoclonal antibodies for pathology, research, and more were developed with support from the NIH Capture Reagents Program grant. Antibodies are proven monospecific against >21,000 human proteins.

2020 – CDI launches VirScan™ & HuScan™ technologies.

First commercial application of phage display immunoprecipitation sequencing technologies.

2020 – CDI develops products for SARS-CoV-2 Research

Release of SARS-COV-2 HuProt™ and funding from Puerto Rico Science Trust to develop tests for the virus that causes COVID-19.

2023 – BroadOak Capital Partners Invests in CDI Laboratories to Expand and Scale Antibody Biomarker Discovery Platforms

The investment will support the expansion of CDI’s technology platforms to service more customers.

2001 – Co-founder Heng Zhu publishes his breakthrough paper featuring the first full eukaryotic proteome array with Michael Snyder.

Global Analysis of Protein Activities Using Proteome Chips. Heng Zhu, et al. Science (2001) DOI: 10.1126/science.1062191

2008 – CDI Labs is founded to commercialize technologies created by the Johns Hopkins University School of Medicine.

Company founded as a collaboration with Johns Hopkins University and a $477K seed grant from the Puerto Rico Science, Technology, and Research Trust.

2009 – Future Director of Proteomic Sciences Shaohui Hu publishes on initial HuProt™ technology with Heng Zhu.

Profiling the Human Protein-DNA Interactome Reveals ERK2 as a Transcriptional Repressor of Interferon Signaling. Shaohui Hu, et al. Cell (2009) DOI: 10.1016/j.cell.2009.08.037

2010 – First SBIR Grant.

SBIR Phase 1 Grant: Development of an Attenuated Babesia Vaccine for Cattle.

2010 – First STTR Grant.

2011 – Future Science Board Member Ben Larman publishes first paper on HuScan™ phage-display immunoprecipitation sequencing.

Application of a synthetic human proteome to autoantigen discovery through PhIP-Seq. H. Benjamin Larman, et al. Nature Biotechnology (2011) DOI: 10.1038/nbt.1856

2011 – Additional funding.

$800K note from the Puerto Rico Science Trust.

2012 – Major $13.5M NIH Roadmap grant to devlop new reagents validated by HuProt™ microarrays.

2012 – First publication of finalized HuProt™ technology.

Rapid identification of monospecific monoclonal antibodies using a human proteome microarray. J Jeong, et al. Molecular & Cellular Proteomics (2012) DOI: 10.1074/mcp.O111.016253

2013 – The first VirD™ prototype was developed in 2013 by CDI’s Director of Proteomic Sciences Shaohui Hu, working with Prashant Desai, Heng Zhu, and others at the Johns Hopkins University School of Medicine.

VirD: A Virion Display Array for Profiling Functional Membrane Proteins. S. Hu, et al. Anal. Chem. (2013) DOI: 10.1021/ac401795y

2015 – CDI invited to attend White House Demo Day.

CEO Ignacio Pino & VP Scott Paschke represents company as a ‘Presidential Ambassador for Global Entrepreneurship’ following invitation by the Obama White House.

2015 – First use of VirScan™ makes international headlines.

Comprehensive serological profiling of human populations using a synthetic human virome. Stephen Elledge, et al. Science (2015) DOI: 10.1126/science.aaa0698

2016 – Results of CDI’s work for the NIH Protein Capture Reagents Program are published in Nature Methods.

The NIH Protein Capture Reagents Program (PCRP): a standardized protein affinity reagent toolbox. S. Blackshaw, et al. Nature Methods. (2016). DOI: 10.1038/nmeth.4013

2016 – Additional STTR Grant.

STTR Phase 1 Grant: Validation of immune-based biomarkers for endometriosis.

2016 – Additional STTR Grant.

STTR Phase 1 Grant: Monospecific monoclonal antibodies against human protein complexes on an interactome- wide scale.

2018 – Collaborators use HuProt™ to show that patients' pre-treatment autoantibody fingerprints can predict adverse events to cancer immunotherapy.

Baseline antibody profiles predict toxicity in melanoma patients treated with immune checkpoint inhibitors. Gowen, et al. J Transl Med (2018) DOI: 10.1186/s12967-018-1452-4

About

News Releases

Company History Timeline

2001 – Co-founder Heng Zhu publishes his breakthrough paper featuring the first full eukaryotic proteome array with Michael Snyder.

2008 – CDI Labs is founded to commercialize technologies created by the Johns Hopkins University School of Medicine.

2009 – Future Director of Proteomic Sciences Shaohui Hu publishes on initial HuProt™ technology with Heng Zhu.

2010 – First SBIR Grant.

2010 – First STTR Grant.

2011 – Additional funding.

2012 – Major $13.5M NIH Roadmap grant to devlop new reagents validated by HuProt™ microarrays.

2012 – First publication of finalized HuProt™ technology.

2013 – The first VirD™ prototype was developed in 2013 by CDI’s Director of Proteomic Sciences Shaohui Hu, working with Prashant Desai, Heng Zhu, and others at the Johns Hopkins University School of Medicine.

2015 – CDI invited to attend White House Demo Day.

2016 – Results of CDI’s work for the NIH Protein Capture Reagents Program are published in Nature Methods.

2016 – Additional STTR Grant.

2016 – Additional STTR Grant.

2018 – Collaborators use HuProt™ to show that patients' pre-treatment autoantibody fingerprints can predict adverse events to cancer immunotherapy.

2019 – Co-founder Heng Zhu publishes additional work on VirD™ membrane-embedded arrays.

2019 – Antygen™ brand launched.

2019 – mMabs™ brand launched.

2020 – CDI launches VirScan™ & HuScan™ technologies.

2020 – CDI develops products for SARS-CoV-2 Research

2023 – BroadOak Capital Partners Invests in CDI Laboratories to Expand and Scale Antibody Biomarker Discovery Platforms

2001 – Co-founder Heng Zhu publishes his breakthrough paper featuring the first full eukaryotic proteome array with Michael Snyder.

2008 – CDI Labs is founded to commercialize technologies created by the Johns Hopkins University School of Medicine.

2009 – Future Director of Proteomic Sciences Shaohui Hu publishes on initial HuProt™ technology with Heng Zhu.

2010 – First SBIR Grant.

2010 – First STTR Grant.

2011 – Future Science Board Member Ben Larman publishes first paper on HuScan™ phage-display immunoprecipitation sequencing.

2011 – Additional funding.

2012 – Major $13.5M NIH Roadmap grant to devlop new reagents validated by HuProt™ microarrays.

2012 – First publication of finalized HuProt™ technology.

2013 – The first VirD™ prototype was developed in 2013 by CDI’s Director of Proteomic Sciences Shaohui Hu, working with Prashant Desai, Heng Zhu, and others at the Johns Hopkins University School of Medicine.

2015 – CDI invited to attend White House Demo Day.

2015 – First use of VirScan™ makes international headlines.

2016 – Results of CDI’s work for the NIH Protein Capture Reagents Program are published in Nature Methods.

2016 – Additional STTR Grant.

2016 – Additional STTR Grant.

2018 – Collaborators use HuProt™ to show that patients' pre-treatment autoantibody fingerprints can predict adverse events to cancer immunotherapy.

2019 – Co-founder Heng Zhu publishes additional work on VirD™ membrane-embedded arrays.

2019 – Antygen™ brand launched.

2019 – Monomabs™ brand launched.

2020 – CDI launches VirScan™ & HuScan™ technologies.

2020 – CDI develops products for SARS-CoV-2 Research